TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT02693535 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

4200

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Multiple Myeloma
Advanced Solid Tumors

Interventions

DRUG: Palbociclib
DRUG: Sunitinib
DRUG: Temsirolimus
DRUG: Trastuzumab and Pertuzumab
DRUG: Vemurafenib and Cobimetinib
DRUG: Regorafenib
DRUG: Olaparib
DRUG: Nivolumab and Ipilimumab
DRUG: Abemaciclib
DRUG: Talazoparib
DRUG: Atezolizumab and Talazoparib
DRUG: Tucatinib plus Trastuzumab Subcutaneous (SC)
DRUG: Futibatinib
DRUG: Dabrafenib plus Trametinib
DRUG: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)

Sponsor

American Society of Clinical Oncology

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]